Safeguarding research integrity and managing fraud risks in the health and life sciences sector

Health and life sciences is rapidly emerging as a major sector in Australia’s economy, helping to drive innovation, advancements in medical treatments, public health and scientific understanding. However, as the sector grows, driven by unprecedent technological change, the industry faces growing risk of fraud and research misconduct, which can have far-reaching consequences for organisations, corporate reputation and public trust.

With likely further regulatory change coming, it is timely to examine the legal, regulatory, and corporate risks associated with failures in research integrity, as well as the proactive measures organisations can adopt to safeguard themselves.

Our fraud & corruption team’s upcoming panel event will explore these themes in detail.

The scope of research integrity failures

With increased recognition and funding comes heightened incentives to engage in misconduct to secure a competitive advantage, status or financial reward. Fraud and misconduct can occur in any industry or organisation, yet health and life sciences face unique challenges owing to the nature of the sector. Rather than conventional fraud, failures in the health and life sciences sector often manifest as fabrication, falsification or plagiarism. While these practices may not appear to the ordinary person to be as corrosive as ordinary fraud, they can lead to devastating outcomes for individuals, organisations and governments, undermining the credibility of research findings, misdirecting funding, and, in the worst cases, jeopardise patient safety.

In Australia, the absence of a dedicated, independent research integrity watchdog has left the sector reliant on self-regulation, which has been criticised for its lack of transparency, conflicts of interest, and inadequate enforcement mechanisms.

The Australian Code for the Responsible Conduct of Research 2018 (Code) provides a framework for responsible research practices, outlining principles such as honesty, rigour, and accountability. However, the Code lacks legislative force and is primarily enforced through institutional policies and funding agreements. This self-regulatory model has been shown to be insufficient in addressing serious breaches of research integrity.

Case studies - lessons from research misconduct

2016 marked a watershed moment for research fraud in Australia, when Bruce Murdoch, a senior academic at the University of Queensland, pleaded guilty to fabricating data for a Parkinson’s disease study. The research, which claimed benefits for patients with speech impairments, was peer‑reviewed, published and used to secure significant grant funding. Only later did it emerge that the study had never occurred; with no participants, trials or legitimate data. Murdoch and his co‑author, Dr Caroline Barwood, were convicted of fraud‑related offences, marking Australia’s first criminal prosecution for research misconduct.

Yet Australia’s experience is not isolated. Like-minded jurisdictions face similar failures, often in high‑profile life sciences contexts; with the prosecution of Elizabeth Holmes in the United States being the clearest example. Theranos attracted extraordinary investment from high-profile backers, enjoyed critical media acclaim and tolerance from regulators long before its technology was independently verified. When its claims collapsed, the case revealed not just individual deception but structural reluctance to challenge success narratives.

Taken together, these cases show that research fraud rarely succeeds because safeguards are missing, but because those safeguards assume honesty. By the time criminal proceedings commence, the damage is done. In both Murdoch and Holmes, fabricated claims passed ethics approval, peer review and funding assessment without challenge. Each stage relied on representations that were false. The cases expose the limits of a system grounded in trust and reputation, particularly where publication drives funding and advancement.

Regulatory landscape and recent developments

Australia’s regulatory framework for research integrity is currently under review, with calls for the establishment of an independent national body, tentatively named Research Integrity Australia (RIA). The proposed body would oversee allegations of research misconduct, provide external assurance, and establish integrity officers within institutions.

While proponents describe the RIA proposal as a step in the right direction, it has also attracted criticism for its limited investigative authority. In particular, concerns have been raised that the body may lack power to conduct independent investigations, instead relying on institutions to investigate themselves. That approach risks entrenching the same conflicts of interest that exist under the current framework. For industry, the consequence may be growing pressure for direct government intervention in governance and regulatory oversight, with the attendant risk of increased compliance costs and regulatory burden.

Corporate risk and internal controls

For organisations operating in the health and life sciences sector, the risks associated with research misconduct extend beyond regulatory penalties. These risks include reputational damage, loss of funding, and potential legal liabilities. The case of GlaxoSmithKline (GSK), which paid a US$3 billion settlement for misrepresenting clinical trial data, serves as a stark reminder of the financial and reputational costs of failing to uphold research integrity.

To mitigate these risks, organisations should consider implementing robust internal controls, including:

• appoint dedicated research integrity officers and independent review panels with real oversight responsibility

• mandate research integrity, ethics and fraud‑prevention training for all staff involved in research

• require clear, auditable transparency in grant applications, ethics approvals and research outputs

• provide secure, confidential reporting channels with practical whistleblower protections

• conduct regular audits of research data and methodologies to identify inconsistencies early

• use independent third parties to verify critical findings and methodologies, and

• enforce strict conflict‑of‑interest identification and management requirements.

Conclusion

As the health and life sciences sector continues to innovate, maintaining research integrity is essential to safeguarding public trust and ensuring the responsible use of resources. Our upcoming Health and Life Sciences: Research Integrity Under the Microscope event provides an opportunity to reflect on the lessons learned from past failures and to explore strategies for fostering a culture of transparency, accountability, and ethical research practices.

By adopting robust internal controls, supporting regulatory reforms, and prioritising early detection and prevention, organisations can not only mitigate the risks of research misconduct but also contribute to a more trustworthy and effective research environment.

If you would like any further information, please contact our fraud & corruption team.

Authors: Gavin Stuart & Zach Bentley

This publication is intended as a source of information only. No reader should act on any matter without first obtaining professional advice.